Principles of Risk Assessment and Monitoring of Antibody Responses to Biopharmaceuticals

Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations

Volumn , Issue , 2011, Pages 1-12

  Koren, Eugen ^a   Foehr, Erik ^a   O'Neill, Charles A ^a  

^a BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

Anti drug antibody (ADA) methods, design and validation drug and ADA complexes; High risk biopharmaceuticals and recombinant human thrombopoietin (rhTPO); Risk based strategies, principles of risk assessment antibody responses, to biopharmaceuticals

Indexed keywords

EID: 84886023233     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118075685.ch1     Document Type: Chapter

References (37)

1. Mire-Sluis, A.R., Barrett, Y.C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., Swanson, S.J., Taniguchi, G., Wierda, D., Zuckerman, L.A. ( 2004 ). Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products . J Immunol Methods, 289, 1-16 .
2. Gupta, S., Indelicato, S.R., Jethwa, V., Kawabata, T., Kelley, M., Mire-Sluis, A.R., Richards, S.M., Rup, B., Shores, E., Swanson, S.J., Wakshull, E. ( 2007 ). Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics . J Immunol Methods, 321, 1-18 .
3. Shankar, G., Devanarayan, V., Amaravadi, L., Barrett, Y.C., Bowsher, R., Finco-Kent, D., Fiscella, M., Gorovits, B., Kirschner, S., Moxness, M., Parish, T., Quarmby, V., Smith, H., Smith, W., Zuckerman, L.A., Koren, E. ( 2008 ). Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products . J Pharm Biomed Anal, 48, 1267-1281 .
4. Koren, E., Smith, H.W., Shores, E., Shankar, G., Finco-Kent, D., Rup, B., Barrett, Y.C., Devanarayan, V., Gorovits, B., Gupta, S., Parish, T., Quarmby, V., Moxness, M., Swanson, S.J., Taniguchi, G., Zuckerman, L.A., Stebbins, C.C., Mire-Sluis, A. ( 2008 ). Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products . J Immunol Methods, 333, 1-9 .
5. Koren, E. ( 2002 ). From characterization of antibodies to prediction of immunogenicity . Dev Biol, 109, 87-95 .
6. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B., Mayeux, P. ( 2002 ). Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin . N Engl J Med, 346, 469-475 .
7. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., Kuter, D.J. ( 2001 ). Thrombocytopenia caused by the development of antibodies to thrombopoietin . Blood, 98, 3241-3248 .
8. Ross, C., Clemmesen, K.M., Svenson, M., Sørensen, P.S., Koch-Henriksen, N., Skovgaard, G.L., Bendtzen, K. ( 2000 ). Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group . Ann Neurol, 48, 706-712 .
9. Koren, E. ( 2003 ). Strategies for the preclinical and clinical characterization of immunogenicity . State of the art methods for the characterization of biological products and assessment of comparability. International Association for Biologics, National Institutes of Health, Bethesda, MD, June 10-13.
10. Zipkin, I. ( 1998). Amgen lays MGDF to rest. BioCentury, 6, A8 .
11. Bennett, C.L., Cournoyer, D., Carson, K.R., Rossert, J., Luminari, S., Evens, A.M., Locatelli, F., Belknap, S.M., McKoy, J.M., Lyons, E.A., Kim, B., Sharma, R., Costello, S., Toffelmire, E.B., Wells, G.A., Messner, H.A., Yarnold, P.R., Trifilio, S.M., Raisch, D.W., Kuzel, T.M., Nissenson, A., Lim, L.C., Tallman, M.S., Casadevall, N. ( 2005 ). Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project . Blood, 106, 3343-3347 .
12. Swanson, S.J., Ferbas, J., Mayeux, P., Casadevall, N. ( 2004 ). Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin . Nephron Clin Pract, 96, c88-c95 .
13. Baert, F., Noman, M., Vermeire, S., Van Assche, G., D'Haens, G., Carbonez, A., Rutgeerts, P. ( 2003 ). Influence of immunogenicity on the long-term efficacy of infliximab in Crohn ' s disease . N Engl J Med, 348, 601-608 .
14. Wolbink, G.J., Vis, M., Lems, W., Voskuyl, A.E., de Groot, E., Nurmohamed, M.T., Stapel, S., Tak, P.P., Aarden, L., Dijkmans, B. ( 2006 ). Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis . Arthritis Rheum, 54, 711-715 .
15. de Vries, M.K., Wolbink, G.J., Stapel, S.O., de Groot, E.R., Dijkmans, B.A., Aarden, L.A., van der Horst-Bruinsma, I.E. ( 2007 ). Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation . Ann Rheum Dis, 66, 133-134 .
16. Radstake, T.R., Svenson, M., Eijsbouts, A.M., van den Hoogen, F.H., Enevold, C., van Riel, P.L., Bendtzen, K. ( 2009 ). Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis . Ann Rheum Dis, 68, 1739-1745 .
17. Bender, N.K., Heilig, C.E., Dröll, B., Wohlgemuth, J., Armbruster, F.P., Heilig, B. ( 2007 ). Immunogenicity, efficacy and adverse events of adalimumab in RA patients . Rheumatol Int, 27, 269-274 .
18. Bartelds, G.M., Wijbrandts, C.A., Nurmohamed, M.T., Stapel, S., Lems, W.F., Aarden, L., Dijkmans, B.A., Tak, P.P., Wolbink, G.J. ( 2007 ). Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis . Ann Rheum Dis, 66, 921-926 .
19. Calabresi, P.A., Giovannoni, G., Confavreux, C., Galetta, S.L., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H., O ' Connor, P.W., Phillips, J.T., Polman, C.H., Radue, E.W., Rudick, R.A., Stuart, W.H., Lublin, F.D., Wajgt, A., Weinstock-Guttman, B., Wynn, D.R., Lynn, F., Panzara, M.A., AFFIRM and SENTINEL Investigators . ( 2007 ). The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL . Neurology, 69, 1391-1403 .
20. Bartelds, G.M., Wijbrandts, C.A., Nurmohamed, M.T., Stapel, S.O., Lems, W.F., Aarden, L., Dijkmans, B.A., Tak, P.P., Wolbink, G.J. ( 2009 ). Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study . Ann Rheum Dis, Aug 13 [Epub ahead of print].
21. Magdelaine-Beuzelin, C., Vermeire, S., Goodall, M., Baert, F., Noman, M., Assche, G.V., Ohresser, M., Degenne, D., Dugoujon, J.M., Jefferis, R., Rutgeerts, P., Lefranc, M.P., Watier, H. ( 2009 ). IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab . Pharmacogenet Genomics, 19, 383-387 .
22. Hayakawa, T., Ishii, A. ( 2011 ). Japanese regulatory perspective on immunogenicity . In Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations . Tovey MG, ed. John Wiley and Sons, New York, chap. 4 (this volume).
23. Koren, E., De Groot, A.S., Jawa, V., Beck, K.D., Boone, T., Rivera, D., Li, L., Mytych, D., Koscec, M., Weeraratne, D., Swanson, S., Martin, W. ( 2007 ). Clinical validation of the " in silico " prediction of immunogenicity of a human recombinant therapeutic protein . Clin Immunol, 124, 26-32 .
24. Barbosa, M.D., Vielmetter, J., Chu, S., Smith, D.D., Jacinto, J. ( 2006 ). Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity . Clin Immunol, 118, 42-50 .
25. Hoffmann, S., Cepok, S., Grummel, V., Lehmann-Horn, K., Hackermüller, J., Stadler, P.F., Hartung, H.P., Berthele, A., Deisenhammer, F., Wassmuth, R., Hemmer, B. ( 2008 ). HLA-DRB1 * 0401 and HLA-DRB1 * 0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis . Am J Hum Genet, 83, 219-227 .
26. Armstrong, J.K., Hempel, G., Koling, S., Chan, L.S., Fisher, T., Meiselman, H.J., Garratty, G. ( 2007 ). Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients . Cancer, 110, 103-111 .
27. White, J.T., Argento Martell, L., Prince, W.S., Boyer, R., Crockett, L., Cox, C., Van Tuyl, A., Aguilera, A., Foehr, E. ( 2008 ). Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the enzyme replacement therapeutic Naglazyme (galsulfase) . AAPS J, 10, 439-449 .
28. Harmatz, P., Giugliani, R., Schwartz, I.V., Guffon, N., Teles, E.L., Miranda, M.C., Wraith, J.E., Beck, M., Arash, L., Scarpa, M., Ketteridge, D., Hopwood, J.J., Plecko, B., Steiner, R., Whitley C.B., Kaplan, P., Yu, Z.F., Swiedler, S.J., Decker, C. ; MPS VI Study Group . ( 2008 ). Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase . Mol Genet Metab, 94, 469-475 .
29. Germain, D.P., Waldek, S., Banikazemi, M., Bushinsky, D.A., Charrow, J., Desnick, R.J., Lee, P., Loew, T., Vedder, A.C., Abichandani, R., Wilcox, W.R., Guffon, N. ( 2007 ). Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease . J Am Soc Nephrol, 18, 1547-1557 .
30. Wraith, J.E., Beck, M., Lane, R., van der Ploeg, A., Shapiro, E., Xue, Y., Kakkis, E.D., Guffon, N. ( 2007 ). Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase) . Pediatrics, 120, e37-e46 .
31. Gouw, S.C., van der Bom, J.G., Auerswald, G., Ettinghausen, C.E., Tedgård, U., van den Berg, H.M. ( 2007 ). Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study . Blood, 109, 4693-4697 .
32. Chitlur, M., Warrier, I., Rajpurkar, M., Lusher, J.M. ( 2009 ). Inhibitors in factor IX deficiency, a report of the ISTH-SSC international FIX inhibitor registry (1997-2006) . Haemophilia, 15, 1027-1031 .
33. Hunley, T.E., Corzo, D., Dudek, M., Kishnani, P., Amalfitano, A., Chen, Y.T., Richards, S.M., Phillips, J.A. 3rd, Fogo, A.B., Tiller, G.E. ( 2004 ). Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease . Pediatrics, 114, e532-e535 .
34. Cross, D.C., Van Der Berg, H.M. ( 2007 ). Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors . Haemophilia, 13, 111-114 .
35. DiMichele, D.M., Kroner, B.L. ( 2002 ). The North American Immune Tolerance Registry: practices, outcomes, outcome predictors: North American Immune Tolerance Study Group . Thromb Haemost, 87, 52-57 .
36. DiMichele, D.M. ( 2006 ). Immune tolerance: critical issues of factor dose, purity and treatment complications . Haemophilia ( Suppl. 6 ), 81-85 .
37. Kishnani, P.S., Goldenberg, P.C., DeArmey, S.L., Heller, J., Benjamin, D., Young, S., Bali, D., Smith, S.A., Li, J.S., Mandel, H., Koeberl, D., Rosenberg, A., Chen, Y-T. ( 2010 ). Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants . Mol Genet Metab, 99, 26-33 .